Open Access Highly Accessed Research article

Expression of SV2 isoforms during rodent brain development

Julie Crèvecœur12, Patrik Foerch5, Melissa Doupagne1, Caroline Thielen1, Catherine Vandenplas5, Gustave Moonen13, Manuel Deprez12 and Bernard Rogister134*

Author Affiliations

1 Laboratory of Developmental Neurobiology, GIGA-Neurosciences, University of Liege, Sart Tilman Liege B-4000, Belgium

2 Laboratory of Neuropathology, GIGA-Neurosciences, University of Liege, Sart Tilman, Liege B-4000, Belgium

3 Departement of Neurology, CHU, University of Liege, Sart Tilman, Liege B-4000, Belgium

4 Laboratory of Developmental Neurobiology, GIGA-Development, Stem Cells and Regenerative Medicine, University of Liege, Sart Tilman, Liege B-4000, Belgium

5 UCB Pharma S.A., CNS Research, Braine-l’Alleud B-1420, Belgium

For all author emails, please log on.

BMC Neuroscience 2013, 14:87  doi:10.1186/1471-2202-14-87

Published: 9 August 2013

Additional files

Additional file 1:

Validation of antibodies anti- SV2A, SV2B, SV2C on WT,SV2A KO (SV2A−/−) and SV2B KO (SV2B−/−) mice at P7. Representative fluorescence images of SV2A, SV2B and SV2C labelling in the hippocampus (H) of WT, SV2A KO (SV2A−/−) and SV2B KO (SV2B−/−) mice at P7. Nuclei were counterstained with DAPI (blue). Original magnification 40X.

Format: TIFF Size: 3MB Download file

Open Data

Additional file 2:

Validation of antibodies anti- SV2A, SV2B, SV2C on SV2A KO (SV2A−/−) mice and using blocking peptide. Fluorescent images of SV2A labelling in the hippocampus (H) of WT, SV2A KO (heterozygous) or SV2A KO (homozygous) mice. For SV2B and SV2C, blocking peptides were used at different concentration (1 ng/mL; 10 ng/mL; 100 ng/mL; 1000 ng/mL). Nuclei were counterstained with DAPI (blue). Substantia Nigra (SN). Original magnification 40X.

Format: TIFF Size: 3MB Download file

Open Data